KCF-18 - 10ml/20mg - Spray

ADVANCED DELIVERY SYSTEM - CELL PENETRATING PEPTIDE TECHNOLOGY 

This product utilizes advanced delivery technology incorporating calibrated cell-penetrating peptide (CPP) systems. The formulation is engineered to support efficient and targeted intracellular delivery of active ingredients, contributing to enhanced transport performance and bioavailability.

SPECIFICATIONS

Product Code: KC1010S

Sequence: H-Lys-Cys-Arg-Lys-Glu-Met-Phe-Lys-Gln-Lys-Leu-Pro-Tyr-Ser-Thr-Val-Tyr-Phe-OH

Molecular Formula: C107H166N26O26S2

Molecular Weight: 2296.74 g/mol

CAS: N/A

Purity: Technical / Research Grade ≥98%

Other details: No TFA Salt

Form: Liquid Solution

Color: Clear / Slightly opalescent

Total Content: 10 mL / 20 mg

Concentration: 2 mg/mL

Approximate Sprays per Bottle: ~82

Approximate Peptide per Spray: ~244 mcg

Vehicle / Carrier System: Proprietary carrier system

Storage Temperature: 4°C (Do not freeze)

Source: Synthetic

Safety classification: Standard handling

DESCRIPTION

Peptide KCF-18 is a multifunctional peptide that has been investigated in experimental and research settings for its interaction with inflammatory signaling pathways.

Designed based on structural motifs derived from the receptors of key inflammatory cytokines—TNF-α, IL-1β, and IL-6—KCF-18 is a multifunctional peptide engineered to interact with multiple cytokine systems. In laboratory models, it has been shown to function as a binding decoy, simultaneously interacting with these cytokines and limiting their ability to bind to their respective receptors. This mechanism enables concurrent modulation of three major pro-inflammatory cytokines, a characteristic that distinguishes KCF-18 from other peptides studied in similar research contexts.

One of the notable properties of KCF-18 observed in experimental studies is its association with reduced vascular inflammatory signaling. This effect has been linked to a decrease in circulating plasma cytokine levels as well as inhibition of monocyte adhesion to endothelial cells. Through these combined actions, KCF-18 has been shown to influence inflammatory processes within vascular models, highlighting its relevance for research focused on vascular inflammation and endothelial function.

Beyond its effects on inflammatory pathways, KCF-18 has also been explored in immunology-focused research models. Experimental findings indicate that KCF-18 can reduce cytokine-induced transmigration of THP-1 cells, suggesting a role in the modulation of immune cell movement and immune response signaling. These observations have positioned KCF-18 as a peptide of interest in studies examining immune regulation and cytokine-mediated cellular interactions.

The structural design of KCF-18 further contributes to its functional profile. The peptide consists of six positively charged N-terminal amino acids derived from TNFR1, six positively charged and hydrophobic amino acids in the central region derived from IL-1R1, and six negatively charged C-terminal amino acids derived from IL-6Rα. This distinct arrangement of charged and hydrophobic regions is believed to support its multifunctional behavior and its ability to interact with multiple cytokine-related targets in experimental systems.

REFERENCES

All observations described above originate from in vitro systems, animal studies, or other preclinical experimental models. They are intended solely to support basic research into molecular, cellular, and physiological mechanisms and do not imply therapeutic, diagnostic, or preventive applications in humans or animals.

Shinn-Jongf Jiang et al., "A potential peptide derived from cytokine receptors can bind proinflammatory cytokines as a therapeutic strategy for anti-inflammation" [Nature]

Chun-Chun Chang et al., "A Multitarget Therapeutic Peptide Derived From Cytokine Receptors Based on in Silico Analysis Alleviates Cytokine-Stimulated Inflammation" [Frontiers]

Hung-Jen Shih et al., "Simultaneous Inhibition of Three Major Cytokines and Its Therapeutic Effects: A Peptide-Based Novel Therapy against Endotoxemia in Mice" [MDPI]

DISCLAIMER

This product is intendend for lab research and development use only. These studies are performed outside of the body. This product is not medicines or drugs and has not been approved by the FDA or EMA to prevent, treat or cure any medical condition, ailment or disease. Bodily introduction of any kind into humans or animals is strictly forbidden by law. This product should only be handled by licensed, qualified professionals.

All product information provided on this website is for informational and educational purposes only.